A panel of US health advisers on Tuesday (US time) endorsed kid-size doses of Pfizer's Covid-19 vaccine, moving the US closer to beginning vaccinations in children ages 5 to 11.
A Food and Drug Administration advisory panel voted unanimously with one abstention that the vaccine's benefits in preventing Covid-19 in that age group outweigh any potential risks — including a heart-related side effect that's been very rare in teens and young adults who get a much higher dose.
The FDA isn't bound by the panel's recommendation and is expected to make its own decision within days.